An overview of the efficacy and safety of β 2 -adrenoceptor antagonists for the treatment of chronic obstructive pulmonary disease.

-ARs, has garnered interest and debate, but further research efforts should focus on elucidating the optimal use of β-AR antagonists in COPD, balancing cardiovascular benefits with potential respiratory risks to enhance outcomes and quality of life for individuals living with this debilitating respiratory condition.